GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Insight Molecular Diagnostics Inc (NAS:IMDX) » Definitions » Cash-to-Debt

IMDX (Insight Molecular Diagnostics) Cash-to-Debt : 8.92 (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Insight Molecular Diagnostics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Insight Molecular Diagnostics's cash to debt ratio for the quarter that ended in Mar. 2025 was 8.92.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Insight Molecular Diagnostics could pay off its debt using the cash in hand for the quarter that ended in Mar. 2025.

The historical rank and industry rank for Insight Molecular Diagnostics's Cash-to-Debt or its related term are showing as below:

IMDX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.84   Med: 5.58   Max: No Debt
Current: 8.92

During the past 12 years, Insight Molecular Diagnostics's highest Cash to Debt Ratio was No Debt. The lowest was 0.84. And the median was 5.58.

IMDX's Cash-to-Debt is ranked better than
78.6% of 215 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.99 vs IMDX: 8.92

Insight Molecular Diagnostics Cash-to-Debt Historical Data

The historical data trend for Insight Molecular Diagnostics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Insight Molecular Diagnostics Cash-to-Debt Chart

Insight Molecular Diagnostics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.91 5.96 5.76 3.29 2.36

Insight Molecular Diagnostics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.67 2.52 0.84 2.36 8.92

Competitive Comparison of Insight Molecular Diagnostics's Cash-to-Debt

For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insight Molecular Diagnostics's Cash-to-Debt Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Insight Molecular Diagnostics's Cash-to-Debt falls into.


;
;

Insight Molecular Diagnostics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Insight Molecular Diagnostics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Insight Molecular Diagnostics's Cash to Debt Ratio for the quarter that ended in Mar. 2025 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Insight Molecular Diagnostics  (NAS:IMDX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Insight Molecular Diagnostics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Insight Molecular Diagnostics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Insight Molecular Diagnostics Business Description

Traded in Other Exchanges
Address
15 Cushing, Irvine, CA, USA, 92618
OncoCyte Corp is a pioneering diagnostics technology company. Its mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers, or payers.
Executives
Broadwood Partners Lp 10 percent owner BROADWOOD CAPITAL INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK NY 10019
Andrew Arno director C/O MERRIMAN CURHAN FORD GROUP, INC., 600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108
Josh Riggs officer: Interim CEO 15 CUSHING, IRVINE CA 92618
John Peter Gutfreund other: Former Director 767 5TH AVENUE, 44TH FLOOR, NEW YORK NY 10153
Alfred D Kingsley director 150 E 57TH STREET, NEW YORK NY 10022
Pura Vida Investments, Llc 10 percent owner 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011
Lou Silverman director
James Yang Liu officer: Controller, PAO C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618
Andrew J. Last director 3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Jennifer L. Carter director C/O DFP SPONSOR LLC, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Ronald Asbury Andrews director 5791 VAN ALLEN WAY, CARLSBAD CA 92008
Melinda Griffith director 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Anish M. John officer: SVP, Finance, and Interim CFO C/O ONCOCYTE CORPORATION,, 15 CUSHING, IRVINE CA 92618
Li Yu officer: VP Cntrllr/Prncpl Acctng Offcr 120 NEWPORT CENTER DRIVE., NEWPORT BEACH CA 92660
Efrem Kamen 10 percent owner C/O PURA VIDA INVESTMENTS, LLC, 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011